EMBARGOED: Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research that will be presented at ASH 2025 on Dec. 8

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

The research team led by Associate Professor Lin-Lin Bu from Wuhan University School and Hospital of Stomatology, has published a comprehensive review entitled “Triaptosis and Cancer: Next Hope?” in the journal Research. This article systematically elaborates the triaptosis pathway from molecular mechanism to therapeutic application, detailing its signaling cascade, discussing the central role of oxidative stress homeostasis in cancer, and offering a forward-looking perspective on future directions—collectively underscoring the compelling potential of triaptosis as a novel anticancer strategy.

A research group led by Drs. Shusuke Tada and Takashi Tsuyama at the Department of Molecular Biology, Faculty of Pharmaceutical Sciences, Toho University, has demonstrated that overexpression of Cdc10-dependent transcript 1 (CDT1), a key regulator of DNA replication initiation, induces DNA damage and potentially results in genetic mutations. Although previous studies have linked CDT1 overexpression to cellular transformation and tumorigenesis, the underlying mechanism has remained unclear. The findings not only reveal the impact of CDT1 overexpression on DNA replication progression post initiation but also provide molecular insights into its role in cancer development.